Clinical trials: Neoadjuvant
Breast Cancer
Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer
The purpose of this research is to test whether bacteria that normally live in the intestines play a role in fighting cancer. It is believed that the development and behavior of these immune cells may be influenced by bacteria…
- Trial name
- NCT02696759
- Testing
- Blood & Fecal Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arkansas
Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
This phase I/II trial studies pembrolizumab and radiation therapy in treating patients with intermediate or high-grade soft tissue sarcoma.
- Trial name
- NCT03338959
- Testing
- Pembrolizumab, Radiation Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Squamous Cell Carcinoma of the Oral Cavity
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21…
- Trial name
- INSPIRE (NCT02609386)
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Where
- 22 sites in United States, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer.
- Conditions
- Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Trial name
- NCT02883062
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 14 sites in United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Locally Advanced Colon Cancer
To determine the Efficacy and Safety of camrelizumab and apatinib combined with chemotherapy (mFOLFOX6) for MSS/pMMR locally advanced colon cancer.
- Trial name
- NCT04625803
- Testing
- Camrelizumab , apatinib and chemotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Zhejiang University
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Oral Squamous Cell Carcinoma
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with resectable local advanced oral squamous cell…
- Trial name
- NEOPBOSCC (NCT04649476)
- Testing
- Camrelizumab, Camrelizumanb plus TPF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Hospital of Stomatology, Wuhan University
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or IIB (to T2) resectable Non-Small Cell Lung…
- Trial name
- NCT00367679
- Testing
- Pazopanib
- Where
- 12 sites in United States, Israel and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections).
- Trial name
- Viale-a (NCT02993523)
- Testing
- Azacitidine, Venetoclax
- Where
- 172 sites in United States, Australia and 27 more
- Volunteers
- 443 people
- Sponsor
- AbbVie